[PDF] Top 20 Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.
Has 10000 "Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients." found on our website. Below are the top 20 most common "Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.".
Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.
... of suppressor cell population, including myeloid derived suppressor cells (MDSCs), able to inhibit T cells ...population in chronic myeloid leukemia ... See full document
10
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients.
... Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy characterized by the t(9;22) chromosomal translocation that generates the BCR/ABL oncogene ...remission in CML ... See full document
13
Mesenchymal stem cells from patients with chronic myeloid leukemia do not express BCR-ABL and have absence of chimerism after allogeneic bone marrow transplant
... digested in 40 to 50 µL lysis buffer (100 mM NaCl, 10 mM Tris HCl, pH ...performed in this ...resulting in a PCR product of 416 bp, and b) for the second reaction 5'-CAGTGTGAAACGGGAGAA AACAGT-3' and ... See full document
11
Chronic myeloid leukemia (CML): prognostic factors and survival analysis
... percent) patients with a follow-up of less than 1 year, and 3 ...ethods. Patients in the chronic or accelerated phase were treated with busulfan or ...until patients returned to the ... See full document
8
Gold nanoparticles for nanotheranostics in leukemia – Addressing Chronic Myeloid Leukemia
... particularly leukemia, show their potential as targets of smart nanomaterials and how much these diseases would benefit from a more personalized approach than current diagnostics and treatment ...foremost, ... See full document
220
J. Bras. Patol. Med. Lab. vol.53 número3
... Introduction: Chronic myeloid leukemia (CML) is a genetic disorder of hematopoietic stem cells, resulting in a myeloproliferative expansion of blood ...parameters in ... See full document
6
Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis
... precursor cells (EPCs), activated circulating endothelial cells (aCECs), and mature circulating endothelial cells (mCECs) using four-color multiparametric flow cytometry in the peripheral ... See full document
6
Detection of mutator phenotype in Brazilian patients with acute and chronic myeloid leukemia
... found in the AML patients had greater lengths than those of the respective control sample, while CML patients had two larger and two smaller new al- leles in the tumoral tissue, as compared to ... See full document
6
Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.
... IkB in cytoplasm, leading to inhibition of the translocation of NFkB from cytoplasm to ...CML cells sensitive or resistant to IM, and exerted synergic effects with histone deacetylase inhibitors and ... See full document
16
Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
... vary in their effects on the sensitivity to standard doses and dose escalations of imatinib and as well as to other TKIs [3,6–7,13,36– ...resistant patients were treated with imatinib dose escalation to ... See full document
9
Circulating myeloid-derived suppressor cells predict disease activity and treatment response in patients with immune thrombocytopenia
... mechanism in the pathogenesis of ITP (1,2). Regulatory T cells (Treg) are characterized as CD4+/FoxP3+ and suppress abnormal T cell activation by secreting TGF-b, IL-10, and IL-4 (among others), thereby ... See full document
6
ANALYSIS OF mRNA TRANSCRIPTS IN CHRONIC MYELOID LEUKEMIA PATIENTS
... established in this work provided excellent amplification of cDNA from BCR/ABL ...33 patients, 25 collected in the chronic phase and 13 in the accelerated phase of the ...disease. ... See full document
6
Acute myeloid leukemia in elderly patients: experience of a single center
... AML in an elderly Brazilian population. Since Brazilian patients differ in ethnic background, endemic infec- tious diseases, socioeconomic aspects and medical support from North American or European ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.34 número5
... study, patients treated with second-generation TKIs had signiicantly higher levels of nitrite and MDA when compared to patients treated with ...TKIs. Patients who are refractory to imatinib had ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.37 número1
... genders. In an analysis using two Joinpoints, sig- nificant drops were observed from 1994 to 2001 (annual percent change: ...for patients aged over 70 years with the age-adjusted mortality rates in ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.39 número2
... expressed lambda chain. Cytogenetic studies of PB for tri- somy 12, del11q23, BCR/ABL1 fusion gene, del17p13.1 (p53) and del13q14.3 molecular abnormalities on fluorescence-activated cell sorting purified CLL-like ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.35 número2
... Although previous studies have employed liquid chromatography to quantify imatinib and its metabolite (CGP74588), the objective of the present study was to develop and fully validate a method that quantiies imatinib and ... See full document
6
Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia
... Methods: Patients with chronic myeloid leukemia were selected to start this new model of ...68 patients with chronic myeloid leukemia and treated with tyronsine ... See full document
10
Rev. Bras. Hematol. Hemoter. vol.35 número2
... transplanted lethally irradiated Balb/c mice with T cell depleted bone marrow and conventional T cells along with azacitidine-treated Tregs, decitabine-treated Tregs or phosphate-buffered saline (PBS)- treated T ... See full document
8
Rev. Bras. Hematol. Hemoter. vol.35 número3
... 160 patients, 100 were ...60 patients who were excluded: 47 started IM treatment in advanced stages of the disease (37 in blast crisis and 10 in accelerated phase) and 13 in ... See full document
6
temas relacionados